Durect completes enrollment in phase 2b ahfirm trial of larsucosterol in alcohol-associated hepatitis

Topline data anticipated in q4 2023 cupertino, calif. , june 7, 2023 /prnewswire/ -- durect corporation (nasdaq: drrx), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic liver diseases, today announced that it has completed enrollment in its phase 2b ahfirm clinical trial (nct04563026) investigating larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (ah), achieving its enrollment target of 300 patients.
DRRX Ratings Summary
DRRX Quant Ranking